Study efficacy of product under study - initestComments 11-09
Study identifier:Disclose11-09
ClinicalTrials.gov identifier:NCT00000001
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
An open-label, multicenter, efficacy study of product
Medical condition
Congestive Heart Failure
Phase
Phase 3
Healthy volunteers
No
Study drug
Pseudodrug
Sex
All
Estimated Enrollment
100
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jan 2020
Estimated Primary Completion Date: 01 Jan 2021
Estimated Study Completion Date: 01 Jan 2022
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2019 by Intrasphere
Sponsors
Intrasphere
Collaborators
-
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Withdrawn
- Other
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Experimental Drug This arm will test the experimental drug pseudodrug at 10mg per dose given every 3 days for 2 weeks | Drug: Pseudodrug Pseudodrug developed by TrialScope for testing study data Other Name: Generic A |
| Active Comparator: Device A Device A to monitor heart funcction | Device: Device A Monitors heart rate Other Name: devia |
Contacts
Investigators
Principal Investigator
Jane Doe
TrialScope Pharmaceuticals
